Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses.

Ballesteros-Briones MC, Martisova E, Casales E, Silva-Pilipich N, Buñuales M, Galindo J, Mancheño U, Gorraiz M, Lasarte JJ, Kochan G, Escors D, Sanchez-Paulete AR, Melero I, Prieto J, Hernandez-Alcoceba R, Hervas-Stubbs S, Smerdou C.

Mol Ther. 2019 Sep 16. pii: S1525-0016(19)30419-8. doi: 10.1016/j.ymthe.2019.09.016. [Epub ahead of print]

PMID:
31563534
2.

Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy.

Zuazo M, Arasanz H, Fernández-Hinojal G, García-Granda MJ, Gato M, Bocanegra A, Martínez M, Hernández B, Teijeira L, Morilla I, Lecumberri MJ, Fernández de Lascoiti A, Vera R, Kochan G, Escors D.

EMBO Mol Med. 2019 Jul;11(7):e10293. doi: 10.15252/emmm.201910293. Epub 2019 Jun 6.

3.

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer.

Bocanegra A, Fernandez-Hinojal G, Zuazo-Ibarra M, Arasanz H, Garcia-Granda MJ, Hernandez C, Ibañez M, Hernandez-Marin B, Martinez-Aguillo M, Lecumberri MJ, Fernandez de Lascoiti A, Teijeira L, Morilla I, Vera R, Escors D, Kochan G.

Int J Mol Sci. 2019 Apr 2;20(7). pii: E1631. doi: 10.3390/ijms20071631.

4.

Radiopotentiation of enzalutamide over human prostate cancer cells as assessed by real-time cell monitoring.

Barrado M, Blanco-Luquin I, Navarrete PA, Visus I, Guerrero-Setas D, Escors D, Kochan G, Arias F.

Rep Pract Oncol Radiother. 2019 Mar-Apr;24(2):221-226. doi: 10.1016/j.rpor.2019.02.002. Epub 2019 Feb 22.

PMID:
30858765
5.

Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies.

Arasanz H, Zuazo M, Vera R, Kochan G, Escors D.

Lung Cancer Manag. 2018 Dec 20;7(3):LMT07. doi: 10.2217/lmt-2018-0014. eCollection 2018 Nov. No abstract available.

6.

The intracellular signalosome of PD-L1 in cancer cells.

Escors D, Gato-Cañas M, Zuazo M, Arasanz H, García-Granda MJ, Vera R, Kochan G.

Signal Transduct Target Ther. 2018 Sep 28;3:26. doi: 10.1038/s41392-018-0022-9. eCollection 2018. Review.

7.

Role of Severe Acute Respiratory Syndrome Coronavirus Viroporins E, 3a, and 8a in Replication and Pathogenesis.

Castaño-Rodriguez C, Honrubia JM, Gutiérrez-Álvarez J, DeDiego ML, Nieto-Torres JL, Jimenez-Guardeño JM, Regla-Nava JA, Fernandez-Delgado R, Verdia-Báguena C, Queralt-Martín M, Kochan G, Perlman S, Aguilella VM, Sola I, Enjuanes L.

MBio. 2018 May 22;9(3). pii: e02325-17. doi: 10.1128/mBio.02325-17.

8.

Characterization of Macrophage Endogenous S-Nitrosoproteome Using a Cysteine-Specific Phosphonate Adaptable Tag in Combination with TiO2 Chromatography.

Ibáñez-Vea M, Huang H, Martínez de Morentin X, Pérez E, Gato M, Zuazo M, Arasanz H, Fernández-Irigoyen J, Santamaría E, Fernandez-Hinojal G, Larsen MR, Escors D, Kochan G.

J Proteome Res. 2018 Mar 2;17(3):1172-1182. doi: 10.1021/acs.jproteome.7b00812. Epub 2018 Jan 25.

PMID:
29338241
9.

Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.

Zuazo M, Gato-Cañas M, Llorente N, Ibañez-Vea M, Arasanz H, Kochan G, Escors D.

Ann Transl Med. 2017 Oct;5(19):385. doi: 10.21037/atm.2017.06.11. Review.

10.

Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives.

Ibáñez-Vea M, Zuazo M, Gato M, Arasanz H, Fernández-Hinojal G, Escors D, Kochan G.

Arch Immunol Ther Exp (Warsz). 2018 Apr;66(2):113-123. doi: 10.1007/s00005-017-0492-4. Epub 2017 Oct 14. Review.

PMID:
29032490
11.

PD1 signal transduction pathways in T cells.

Arasanz H, Gato-Cañas M, Zuazo M, Ibañez-Vea M, Breckpot K, Kochan G, Escors D.

Oncotarget. 2017 Apr 19;8(31):51936-51945. doi: 10.18632/oncotarget.17232. eCollection 2017 Aug 1. Review.

12.

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity.

Gato-Cañas M, Zuazo M, Arasanz H, Ibañez-Vea M, Lorenzo L, Fernandez-Hinojal G, Vera R, Smerdou C, Martisova E, Arozarena I, Wellbrock C, Llopiz D, Ruiz M, Sarobe P, Breckpot K, Kochan G, Escors D.

Cell Rep. 2017 Aug 22;20(8):1818-1829. doi: 10.1016/j.celrep.2017.07.075.

13.

Immunotherapy in malignant melanoma: recent approaches and new perspectives.

Arasanz H, Lacalle A, Lecumberri MJ, de Lascoiti ÁF, Blanco-Luquin I, GatoCañas M, Pérez-Ricarte L, Zuazo M, Kochan G, Escors D.

Melanoma Manag. 2017 Mar;4(1):39-48. doi: 10.2217/mmt-2016-0019. Epub 2017 Mar 1. Review.

14.

Novel immunotherapies for the treatment of melanoma.

Gato-Cañas M, Arasanz H, Blanco-Luquin I, Glaría E, Arteta-Sanchez V, Kochan G, Escors D.

Immunotherapy. 2016 May;8(5):613-32. doi: 10.2217/imt-2015-0024. Review.

PMID:
27140413
15.

[Dendritic cells in cancer immunotherapy].

Gato M, Liechtenstein T, Blanco-Luquín I, Zudaire MI, Kochan G, Escors D.

An Sist Sanit Navar. 2015 May-Aug;38(2):279-87. Spanish.

16.

Drafting the proteome landscape of myeloid-derived suppressor cells.

Gato M, Blanco-Luquin I, Zudaire M, de Morentin XM, Perez-Valderrama E, Zabaleta A, Kochan G, Escors D, Fernandez-Irigoyen J, Santamaría E.

Proteomics. 2016 Jan;16(2):367-78. doi: 10.1002/pmic.201500229. Epub 2015 Dec 14. Review.

PMID:
26403437
17.

A core of kinase-regulated interactomes defines the neoplastic MDSC lineage.

Gato-Cañas M, Martinez de Morentin X, Blanco-Luquin I, Fernandez-Irigoyen J, Zudaire I, Liechtenstein T, Arasanz H, Lozano T, Casares N, Chaikuad A, Knapp S, Guerrero-Setas D, Escors D, Kochan G, Santamaría E.

Oncotarget. 2015 Sep 29;6(29):27160-75. doi: 10.18632/oncotarget.4746.

18.

Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis.

Perez-Janices N, Blanco-Luquin I, Torrea N, Liechtenstein T, Escors D, Cordoba A, Vicente-Garcia F, Jauregui I, De La Cruz S, Illarramendi JJ, Coca V, Berdasco M, Kochan G, Ibañez B, Lera JM, Guerrero-Setas D.

Oncotarget. 2015 Sep 15;6(27):23944-58.

19.

Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase.

Rydzik AM, Brem J, Struwe WB, Kochan GT, Benesch JL, Schofield CJ.

Bioorg Med Chem Lett. 2014 Nov 1;24(21):4954-7. doi: 10.1016/j.bmcl.2014.09.035. Epub 2014 Sep 19.

PMID:
25266780
20.

Oxygenase-catalyzed desymmetrization of N,N-dialkyl-piperidine-4-carboxylic acids.

Rydzik AM, Leung IK, Kochan GT, McDonough MA, Claridge TD, Schofield CJ.

Angew Chem Int Ed Engl. 2014 Oct 6;53(41):10925-7. doi: 10.1002/anie.201406125. Epub 2014 Aug 27.

21.

A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice.

Liechtenstein T, Perez-Janices N, Gato M, Caliendo F, Kochan G, Blanco-Luquin I, Van der Jeught K, Arce F, Guerrero-Setas D, Fernandez-Irigoyen J, Santamaria E, Breckpot K, Escors D.

Oncotarget. 2014 Sep 15;5(17):7843-57.

22.

Comparison of the substrate selectivity and biochemical properties of human and bacterial γ-butyrobetaine hydroxylase.

Rydzik AM, Leung IK, Kochan GT, Loik ND, Henry L, McDonough MA, Claridge TD, Schofield CJ.

Org Biomol Chem. 2014 Sep 7;12(33):6354-8. doi: 10.1039/c4ob01167h.

PMID:
25030770
23.

Modulating carnitine levels by targeting its biosynthesis pathway - selective inhibition of γ-butyrobetaine hydroxylase.

Rydzik AM, Chowdhury R, Kochan GT, Williams ST, McDonough MA, Kawamura A, Schofield CJ.

Chem Sci. 2014 May 1;5(5):1765-1771.

24.

Role of non-classical MHC class I molecules in cancer immunosuppression.

Kochan G, Escors D, Breckpot K, Guerrero-Setas D.

Oncoimmunology. 2013 Nov 1;2(11):e26491. Epub 2013 Oct 21. Review.

25.

Fluoromethylated derivatives of carnitine biosynthesis intermediates--synthesis and applications.

Rydzik AM, Leung IK, Thalhammer A, Kochan GT, Claridge TD, Schofield CJ.

Chem Commun (Camb). 2014 Feb 7;50(10):1175-7. doi: 10.1039/c3cc47581f.

PMID:
24317009
26.

Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?

Escors D, Liechtenstein T, Perez-Janices N, Schwarze J, Dufait I, Goyvaerts C, Lanna A, Arce F, Blanco-Luquin I, Kochan G, Guerrero-Setas D, Breckpot K.

Oncoimmunology. 2013 Oct 1;2(10):e26148. Epub 2013 Sep 12. Review.

27.

Immune modulation by genetic modification of dendritic cells with lentiviral vectors.

Liechtenstein T, Perez-Janices N, Bricogne C, Lanna A, Dufait I, Goyvaerts C, Laranga R, Padella A, Arce F, Baratchian M, Ramirez N, Lopez N, Kochan G, Blanco-Luquin I, Guerrero-Setas D, Breckpot K, Escors D.

Virus Res. 2013 Sep;176(1-2):1-15. doi: 10.1016/j.virusres.2013.05.007. Epub 2013 May 28. Review.

PMID:
23726846
28.

Development and application of a fluoride-detection-based fluorescence assay for γ-butyrobetaine hydroxylase.

Rydzik AM, Leung IK, Kochan GT, Thalhammer A, Oppermann U, Claridge TD, Schofield CJ.

Chembiochem. 2012 Jul 23;13(11):1559-63. doi: 10.1002/cbic.201200256. Epub 2012 Jun 22.

PMID:
22730246
29.

Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.

Rose NR, Woon EC, Tumber A, Walport LJ, Chowdhury R, Li XS, King ON, Lejeune C, Ng SS, Krojer T, Chan MC, Rydzik AM, Hopkinson RJ, Che KH, Daniel M, Strain-Damerell C, Gileadi C, Kochan G, Leung IK, Dunford J, Yeoh KK, Ratcliffe PJ, Burgess-Brown N, von Delft F, Muller S, Marsden B, Brennan PE, McDonough MA, Oppermann U, Klose RJ, Schofield CJ, Kawamura A.

J Med Chem. 2012 Jul 26;55(14):6639-43. doi: 10.1021/jm300677j. Epub 2012 Jul 11.

30.

Crystal structure of the secretory isozyme of mammalian carbonic anhydrases CA VI: implications for biological assembly and inhibitor development.

Pilka ES, Kochan G, Oppermann U, Yue WW.

Biochem Biophys Res Commun. 2012 Mar 16;419(3):485-9. doi: 10.1016/j.bbrc.2012.02.038. Epub 2012 Feb 14.

PMID:
22366092
31.

On the Mechanism of T cell receptor down-modulation and its physiological significance.

Escors D, Bricogne C, Arce F, Kochan G, Karwacz K.

J Biosci Med. 2011 Jan;1(1). pii: 2011.5.

32.

PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy.

Karwacz K, Arce F, Bricogne C, Kochan G, Escors D.

Oncoimmunology. 2012 Jan 1;1(1):86-88.

33.

Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility.

Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, Kochan G, Oppermann U, Dilthey A, Pirinen M, Stone MA, Appleton L, Moutsianas L, Leslie S, Wordsworth T, Kenna TJ, Karaderi T, Thomas GP, Ward MM, Weisman MH, Farrar C, Bradbury LA, Danoy P, Inman RD, Maksymowych W, Gladman D, Rahman P; Spondyloarthritis Research Consortium of Canada (SPARCC), Morgan A, Marzo-Ortega H, Bowness P, Gaffney K, Gaston JS, Smith M, Bruges-Armas J, Couto AR, Sorrentino R, Paladini F, Ferreira MA, Xu H, Liu Y, Jiang L, Lopez-Larrea C, Díaz-Peña R, López-Vázquez A, Zayats T, Band G, Bellenguez C, Blackburn H, Blackwell JM, Bramon E, Bumpstead SJ, Casas JP, Corvin A, Craddock N, Deloukas P, Dronov S, Duncanson A, Edkins S, Freeman C, Gillman M, Gray E, Gwilliam R, Hammond N, Hunt SE, Jankowski J, Jayakumar A, Langford C, Liddle J, Markus HS, Mathew CG, McCann OT, McCarthy MI, Palmer CN, Peltonen L, Plomin R, Potter SC, Rautanen A, Ravindrarajah R, Ricketts M, Samani N, Sawcer SJ, Strange A, Trembath RC, Viswanathan AC, Waller M, Weston P, Whittaker P, Widaa S, Wood NW, McVean G, Reveille JD, Wordsworth BP, Brown MA, Donnelly P; Australo-Anglo-American Spondyloarthritis Consortium (TASC); Wellcome Trust Case Control Consortium 2 (WTCCC2).

Nat Genet. 2011 Jul 10;43(8):761-7. doi: 10.1038/ng.873. Erratum in: Nat Genet. 2011 Sep;43(9):919. Opperman, Udo [corrected to Oppermann, Udo]; Moutsianis, Loukas [corrected to Moutsianas, Loukas].

34.

Selective activation of intracellular signalling pathways in dendritic cells for cancer immunotherapy.

Arce F, Kochan G, Breckpot K, Stephenson H, Escors D.

Anticancer Agents Med Chem. 2012 Jan;12(1):29-39. Review.

PMID:
21707504
35.

Crystal structure of PHYHD1A, a 2OG oxygenase related to phytanoyl-CoA hydroxylase.

Zhang Z, Kochan GT, Ng SS, Kavanagh KL, Oppermann U, Schofield CJ, McDonough MA.

Biochem Biophys Res Commun. 2011 May 20;408(4):553-8. doi: 10.1016/j.bbrc.2011.04.059. Epub 2011 Apr 21.

PMID:
21530488
36.

Crystal structures of the endoplasmic reticulum aminopeptidase-1 (ERAP1) reveal the molecular basis for N-terminal peptide trimming.

Kochan G, Krojer T, Harvey D, Fischer R, Chen L, Vollmar M, von Delft F, Kavanagh KL, Brown MA, Bowness P, Wordsworth P, Kessler BM, Oppermann U.

Proc Natl Acad Sci U S A. 2011 May 10;108(19):7745-50. doi: 10.1073/pnas.1101262108. Epub 2011 Apr 20.

37.

Structural and mechanistic studies on γ-butyrobetaine hydroxylase.

Leung IK, Krojer TJ, Kochan GT, Henry L, von Delft F, Claridge TD, Oppermann U, McDonough MA, Schofield CJ.

Chem Biol. 2010 Dec 22;17(12):1316-24. doi: 10.1016/j.chembiol.2010.09.016.

38.

Structures of the human GTPase MMAA and vitamin B12-dependent methylmalonyl-CoA mutase and insight into their complex formation.

Froese DS, Kochan G, Muniz JR, Wu X, Gileadi C, Ugochukwu E, Krysztofinska E, Gravel RA, Oppermann U, Yue WW.

J Biol Chem. 2010 Dec 3;285(49):38204-13. doi: 10.1074/jbc.M110.177717. Epub 2010 Sep 28.

39.

Crystal Structure of the 2-Oxoglutarate- and Fe(II)-Dependent Lysyl Hydroxylase JMJD6.

Mantri M, Krojer T, Bagg EA, Webby CA, Butler DS, Kochan G, Kavanagh KL, Oppermann U, McDonough MA, Schofield CJ.

J Mol Biol. 2010 May 31. [Epub ahead of print]

PMID:
20685276
40.

Crystal structure of the 2-oxoglutarate- and Fe(II)-dependent lysyl hydroxylase JMJD6.

Mantri M, Krojer T, Bagg EA, Webby CJ, Butler DS, Kochan G, Kavanagh KL, Oppermann U, McDonough MA, Schofield CJ.

J Mol Biol. 2010 Aug 13;401(2):211-22.

PMID:
20684070
41.

Structural impact of human and Escherichia coli biotin carboxyl carrier proteins on biotin attachment.

Healy S, McDonald MK, Wu X, Yue WW, Kochan G, Oppermann U, Gravel RA.

Biochemistry. 2010 Jun 8;49(22):4687-94. doi: 10.1021/bi901612y.

PMID:
20443544
42.

Thermolability of mutant MMACHC protein in the vitamin B12-responsive cblC disorder.

Froese DS, Healy S, McDonald M, Kochan G, Oppermann U, Niesen FH, Gravel RA.

Mol Genet Metab. 2010 May;100(1):29-36. doi: 10.1016/j.ymgme.2010.02.005. Epub 2010 Feb 15.

43.

Structural basis for substrate specificity in human monomeric carbonyl reductases.

Pilka ES, Niesen FH, Lee WH, El-Hawari Y, Dunford JE, Kochan G, Wsol V, Martin HJ, Maser E, Oppermann U.

PLoS One. 2009 Oct 20;4(10):e7113. doi: 10.1371/journal.pone.0007113.

44.

Structural basis for different specificities of acyltransferases associated with the human cytosolic and mitochondrial fatty acid synthases.

Bunkoczi G, Misquitta S, Wu X, Lee WH, Rojkova A, Kochan G, Kavanagh KL, Oppermann U, Smith S.

Chem Biol. 2009 Jun 26;16(6):667-75. doi: 10.1016/j.chembiol.2009.04.011.

45.

Crystal structure of human carbonic anhydrase-related protein VIII reveals the basis for catalytic silencing.

Picaud SS, Muniz JR, Kramm A, Pilka ES, Kochan G, Oppermann U, Yue WW.

Proteins. 2009 Aug 1;76(2):507-11. doi: 10.1002/prot.22411. No abstract available.

PMID:
19360879
46.

Structural snapshots for the conformation-dependent catalysis by human medium-chain acyl-coenzyme A synthetase ACSM2A.

Kochan G, Pilka ES, von Delft F, Oppermann U, Yue WW.

J Mol Biol. 2009 May 22;388(5):997-1008. doi: 10.1016/j.jmb.2009.03.064. Epub 2009 Apr 1.

PMID:
19345228
47.

Membrane cell fusion activity of the vaccinia virus A17-A27 protein complex.

Kochan G, Escors D, González JM, Casasnovas JM, Esteban M.

Cell Microbiol. 2008 Jan;10(1):149-64. Epub 2007 Aug 15.

48.

Formation of Pseudorabies virus glycoprotein E/I complex in baculovirus recombinant system.

Tyborowska J, Reszka N, Kochan G, Szewczyk B.

Acta Virol. 2006;50(3):169-74.

PMID:
17131935
49.

MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis.

Pérez-Jiménez E, Kochan G, Gherardi MM, Esteban M.

Microbes Infect. 2006 Mar;8(3):810-22. Epub 2006 Jan 13.

PMID:
16504562
50.

Supplemental Content

Loading ...
Support Center